Novartis discontinues ALS drug trial after failure
Bloomberg News reports Novartis discontinued development of an experimental ALS medicine after a mid-stage trial failed to show it worked better than a dummy drug in delaying disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.